{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:48:31Z","timestamp":1778600911365,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.canep.2025.102800","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T20:17:38Z","timestamp":1742069858000},"page":"102800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study"],"prefix":"10.1016","volume":"96","author":[{"given":"J.","family":"Passildas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MJ","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Uwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Dohollou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Petit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hajjaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Boudin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Lorgis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JP","family":"Jacquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Abrial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MA","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2025.102800_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.canep.2025.102800_bib2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the United States","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"10.1016\/j.canep.2025.102800_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005\u20132015)","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.canep.2025.102800_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.rpor.2013.01.001","article-title":"Prognostic factors and survival in metastatic breast cancer: A single institution experience","volume":"18","author":"Khanfir","year":"2013","journal-title":"Rep. Pract. Oncol. Radiother. J. Gt. Cancer Cent. Pozn. Pol. Soc. Radiat. Oncol."},{"key":"10.1016\/j.canep.2025.102800_bib5","first-page":"641","article-title":"Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer","volume":"46","author":"Mani","year":"2010","journal-title":"Drugs Today Barc. Spain 1998"},{"key":"10.1016\/j.canep.2025.102800_bib6","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canep.2025.102800_bib7","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","article-title":"Inhibition of Centromere Dynamics by Eribulin (E7389) during mitotic metaphase","volume":"7","author":"Okouneva","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canep.2025.102800_bib8","doi-asserted-by":"crossref","first-page":"6615","DOI":"10.1158\/1078-0432.CCR-11-1807","article-title":"Eribulin Mesylate","volume":"17","author":"Jain","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canep.2025.102800_bib9","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1158\/1078-0432.CCR-08-2429","article-title":"A Phase I Study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies","volume":"15","author":"Goel","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canep.2025.102800_bib10","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1158\/1078-0432.CCR-09-0360","article-title":"Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canep.2025.102800_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.3036","article-title":"A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial","volume":"23","author":"Synold","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2025.102800_bib12","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canep.2025.102800_bib13","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canep.2025.102800_bib14","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.canep.2025.102800_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.canep.2025.102800_bib16","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice Versus E7389) investigators, Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.canep.2025.102800_bib17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-014-3144-y","article-title":"Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies","volume":"148","author":"Twelves","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canep.2025.102800_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2025.102800_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","article-title":"The lasso method for variable selection in the Cox model","volume":"16","author":"Tibshirani","year":"1997","journal-title":"Stat. Med."},{"key":"10.1016\/j.canep.2025.102800_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12885-021-09137-0","article-title":"Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study","volume":"22","author":"Nakamoto","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canep.2025.102800_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000489061","article-title":"Long-term response with eribulin mesylate in a breast cancer patient: a case report","volume":"94","author":"Medici","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.canep.2025.102800_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211030210","article-title":"Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study","volume":"13","author":"Zhao","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.canep.2025.102800_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000489063","article-title":"Eribulin in heavily pretreated metastatic breast cancer patients in the real world: a retrospective study","volume":"94","author":"Pedersini","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.canep.2025.102800_bib24","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.7150\/ijms.54996","article-title":"Second-line eribulin in triple negative metastatic breast cancer patients. multicentre retrospective study: the TETRIS Trial","volume":"18","author":"Krasniqi","year":"2021","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.canep.2025.102800_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1159\/000526140","article-title":"Eribulin treatment for patients with metastatic breast cancer: the UK experience - a multicenter retrospective study","volume":"100","author":"Jafri","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.canep.2025.102800_bib26","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1038\/s41467-022-30569-0","article-title":"Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer","volume":"13","author":"Liu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canep.2025.102800_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-66980-0","article-title":"Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis","volume":"10","author":"O\u2019Shaughnessy","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canep.2025.102800_bib28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.2217\/fon-2018-0936","article-title":"Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer","volume":"15","author":"O\u2019Shaughnessy","year":"2019","journal-title":"Future Oncol. Lond. Engl."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782125000608?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782125000608?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T21:30:48Z","timestamp":1747258248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782125000608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"alternative-id":["S1877782125000608"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2025.102800","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2025.102800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102800"}}